No Data
No Data
Top Premarket Decliners
We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Stoke Therapeutics (STOK) and Lantheus (LNTH)
A Quick Look at Today's Ratings for Stoke Therapeutics(STOK.US), With a Forecast Between $22 to $47
Biogen and Stoke Therapeutics to Commercialise Dravet Syndrome Treatment
Unlock the Full List